ArticleTherapeutic innovation & regulatory science2026
Clinical and Economic Burden of Diseases with Accelerated Approval Therapies: Evidence of Unmet Patient Need.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome US payers delay coverage for non-oncology treatments approved via the Food and Drug Administration (FDA)'s accelerated approval (AA) pathway.
objectivesTo estimate the economic burden and characteristics of diseases with therapies approved via the AA pathway compared to diseases with no AA therapies.
methodsThe study identified the initial FDA-approved AA indications for all non-oncology therapies from January 2015 to February 2025. For comparison, 100 non-oncology diseases with the most recent FDA-approved non-AA therapies were identified. Annual economic burden and disease characteristics were extracted from peer-reviewed literature, with costs inflated to 2025 USD. Economic burden studies that used a societal perspective were prioritized. Comparative analyses were conducted using the Mann-Whitney U Test.
resultsThirty-two non-oncology AA treatments were identified representing 16 unique diseases. Average annual incremental societal costs for AA diseases were 1.4 times higher than for non-AA diseases ($91,857 vs. $65,468, p = 0.012). Additionally, the annual average productivity loss and caregiver burden were 1.8 times ($17,635 vs. $9,620, p = 0.092) and 2.4 times ($20,268 vs. $8,294, p = 0.055) greater in the AA diseases, respectively. Diseases with newly-approved AA treatments were characterized by shorter life expectancy (59.3 vs 65.1 years), lower average quality of life (0.64 vs 0.69), and more likely to be rare diseases (68.8% vs 53.1%) compared to non-AA diseases.
conclusionNon-oncology diseases with treatments approved via the AA pathway imposed a higher economic burden and had more severe disease characteristics compared to non-AA diseases. These findings should be considered alongside AA coverage policy decision-making.
Indexed as
Identifiers
42570073What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.